Abstract

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown. Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentially provide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRI ΔR2* relaxivity measurements offer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-κB reporter gene system provides NF-κB activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit the tumor growth and NF-κB-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together, dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.

Original languageEnglish
Pages (from-to)1019-1031
Number of pages13
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number3
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

NF-kappa B
Magnetic resonance
Reporter Genes
Nanoparticles
Lung Neoplasms
Genes
Magnetic Resonance Imaging
Imaging techniques
Non-Small Cell Lung Carcinoma
Monitoring
Drug delivery
Iron oxides
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Magnetic resonance imaging
Tumors
Drug Monitoring
Chemical activation
Cells
Therapeutics

Keywords

  • Erlotinib
  • Magnetic resonance imaging
  • Non-small-cell lung cancer
  • Nuclear factor-κB
  • Superparamagnetic iron oxide

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

@article{5094304a05de4dde86492a29299f0024,
title = "Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system",
abstract = "Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown. Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentially provide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRI ΔR2* relaxivity measurements offer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-κB reporter gene system provides NF-κB activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit the tumor growth and NF-κB-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together, dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.",
keywords = "Erlotinib, Magnetic resonance imaging, Non-small-cell lung cancer, Nuclear factor-κB, Superparamagnetic iron oxide",
author = "Hsu, {Fei Ting} and Liu, {Hua Shan} and Ali, {Ahmed Atef Ahmed} and Tsai, {Ping Huei} and Kao, {Yu Chieh} and Lu, {Chia Feng} and Huang, {Hsu Shan} and Chen, {Cheng Yu}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.nano.2018.01.010",
language = "English",
volume = "14",
pages = "1019--1031",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system

AU - Hsu, Fei Ting

AU - Liu, Hua Shan

AU - Ali, Ahmed Atef Ahmed

AU - Tsai, Ping Huei

AU - Kao, Yu Chieh

AU - Lu, Chia Feng

AU - Huang, Hsu Shan

AU - Chen, Cheng Yu

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown. Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentially provide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRI ΔR2* relaxivity measurements offer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-κB reporter gene system provides NF-κB activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit the tumor growth and NF-κB-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together, dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.

AB - Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown. Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentially provide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRI ΔR2* relaxivity measurements offer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-κB reporter gene system provides NF-κB activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit the tumor growth and NF-κB-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together, dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.

KW - Erlotinib

KW - Magnetic resonance imaging

KW - Non-small-cell lung cancer

KW - Nuclear factor-κB

KW - Superparamagnetic iron oxide

UR - http://www.scopus.com/inward/record.url?scp=85042699094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042699094&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.01.010

DO - 10.1016/j.nano.2018.01.010

M3 - Article

AN - SCOPUS:85042699094

VL - 14

SP - 1019

EP - 1031

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 3

ER -